<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[AAVizion]]></title><description><![CDATA[Visionary Solutions in Gene Therapy]]></description><link>https://www.aavizion.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Thu, 06 Aug 2026 08:44:08 GMT</lastBuildDate><atom:link href="https://www.aavizion.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[FDA Potency Guidance for Cell and Gene Therapy: Implications for Ocular AAV Programs]]></title><description><![CDATA[The FDA's draft guidance, Potency Assurance for Cellular and Gene Therapy Products, represents an important shift in how cell and gene therapy developers should approach potency throughout product development. Although the guidance applies broadly across the field, several recommendations are especially relevant to ocular AAV programs. Rather than viewing potency as a single laboratory assay, the FDA emphasizes a comprehensive potency assurance strategy that evolves with the program. This...]]></description><link>https://www.aavizion.com/post/test</link><guid isPermaLink="false">6a723b192b9f850aae003967</guid><category><![CDATA[Regulatory & CMC]]></category><pubDate>Tue, 04 Aug 2026 19:18:53 GMT</pubDate><dc:creator>Parvaneh Katoli</dc:creator></item></channel></rss>